Satellos Bioscience Inc.
MSLE
Positions held
Your positionsMSLE isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $155.83M | Enterprise value | $94.00M | Trailing P/E | — | Forward P/E | -2.60 |
| PEG | — | Price / book | 2.55 | Beta | 1.15 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -70.4% | ROA | -41.9% | Debt / equity | — |
| Current ratio | 11.22 | Free cash flow | -$16.92M | Analyst recommendation | strong_buy | Mean target | $25.80 |
| 52w high | $13.40 | 52w low | $5.30 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$11.7M | -$9.8M | -$7.3M | -$5.8M | -$5.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.2M | -$10.0M | -$7.6M | -$6.0M | -$6.4M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$24.9M | -$20.6M | -$12.0M | -$8.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | -$0.1M |
| Operating income | -$26.5M | -$20.4M | -$11.7M | -$6.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Satellos Bioscience Granted Composition of Matter Patent for Forazapadin by USPTO
2026-10-05 · Satellos Granted Composition of Matter Patent for Forazapadin
2026-09-30 · Satellos Bioscience Completes Enrollment in Phase 2 Basecamp Trial
2026-09-24 · Satellos Receives FDA Clearance For FSHD Investigational New Drug Application
2026-09-24 · Satellos Receives FDA Clearance to Study Forazapadin in FSHD
2026-09-24 · Satellos stock jumps after FDA clears FSHD trial for forazapadin
2026-09-15 · Satellos to Present at the 31st Annual Congress of the World Muscle Society
2026-09-09 · Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
2026-09-01 · Satellos to Participate in Upcoming Investor Conferences
2026-08-25 · LifeSci Capital Initiates Satellos Bioscience at Outperform
Price (daily)
Full chart · RSI · MACD · patterns